title: The percentage of patients with seronegative spondyloarthritis requiring magnetic resonance imaging to meet the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines for access to anti-tumor necrosis factor treatment.
abstract: OBJECTIVE
  To determine what percentage of patients would require a magnetic resonance imaging (MRI) scan to qualify for treatment in a Canadian tertiary care setting.
  
  
  METHODS
  Consecutive patients with established axial seronegative spondyloarthropathy were recruited. Patients completed a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath AS Functional Inquiry (BASFI) questionnaire and the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level were measured. Patients were categorized into groups, those who would qualify for anti-tumor necrosis factor (TNF) agents without an MRI, those who would require an MRI to determine eligibility, and those who would not qualify, even with active inflammation on an MRI.
  
  
  RESULTS
  Twenty-nine patients were recruited in a 1-year period and 12 (41.3%; 95% confidence interval 25.5%-59.3%) would require an MRI to gain access to an anti-TNF agent. Extrapolating published estimates of prevalence of seronegative arthritis and AS and assuming 1/3 will have severe resistant disease, about 9000 patients in Canada would require an MRI to determine eligibility for anti-TNF treatment.
  
  
  CONCLUSIONS
  Canada currently ranks 13/22 countries studied in terms of MRI resources per capita. Given the limited MRI resources in Canada, Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines could present an additional barrier to timely treatment in 41% of patients.
authors.affiliation: Division of Rheumatology and the Department of Medicine, the University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Leticia
authors.initials: L
authors.lastname: Troppmann
authors.forename: Jacob
authors.initials: J
authors.lastname: Karsh
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002170:Canada; D003657:Decision Making; D005260:Female; D006297:Health Services Accessibility; D006305:Health Status Indicators; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods* / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index; D025241:Spondylarthritis / Q000188:drug therapy / Q000473:pathology*; D011795:Surveys and Questionnaires; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha